Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

CPRX has been the topic of several other reports. Zacks Investment Research downgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. SunTrust Banks reissued a “buy” rating and set a $5.00 target price on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $8.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $6.25.

Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $4.01 on Thursday. Catalyst Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.51.

A number of hedge funds have recently added to or reduced their stakes in CPRX. Nationwide Fund Advisors bought a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $111,000. New York State Common Retirement Fund bought a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $114,000. Bank of New York Mellon Corp boosted its holdings in Catalyst Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after acquiring an additional 2,404 shares during the period. SG Americas Securities LLC bought a new stake in Catalyst Pharmaceuticals during the third quarter valued at about $144,000. Finally, State of Wisconsin Investment Board bought a new stake in Catalyst Pharmaceuticals during the second quarter valued at about $149,000. Institutional investors own 35.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Catalyst Pharmaceuticals (CPRX) Lowered to “Buy” at BidaskClub” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.watchlistnews.com/catalyst-pharmaceuticals-cprx-lowered-to-buy-at-bidaskclub/1748655.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.